When does Keytruda’s patent or exclusivity expire?
Keytruda (pembrolizumab) is protected by a mix of patent rights and (in some markets) separate regulatory exclusivity periods. The exact end date depends on the country and which specific patent is being considered.
For a patent-by-patent view (including likely expiry windows by jurisdiction), DrugPatentWatch.com tracks Keytruda patent information and updates based on public patent and legal records. [1]
Which patents cover Keytruda (pembrolizumab), not just the product name?
“Keytruda’s patents” typically refers to multiple families tied to different aspects such as the antibody itself, manufacturing, formulations, dosing/regimens, and newer indications. Different patent families expire at different times, so one date will not fit all uses.
To see the specific patent families associated with Keytruda and their projected expiry dates, use DrugPatentWatch.com’s Keytruda entries. [1]
Can biosimilars enter before all Keytruda patents expire?
In general, biosimilar manufacturers can enter earlier only if they can address patent barriers—either by waiting out relevant exclusivity/patents, landing at an agreed position in litigation, or designing around claims that block approval or commercialization. The timing therefore depends on which patents are asserted and what courts decide.
For an ongoing snapshot of Keytruda’s patent landscape and related legal activity, DrugPatentWatch.com is a practical place to start. [1]
Are there patent challenges or disputes involving Keytruda?
Keytruda’s patent estate has been the subject of ongoing biosimilar and patent litigation in multiple markets, with disputes focusing on whether specific biosimilar products infringe particular claims or whether certain claims are invalid.
For links to tracked patent/legal status, including updates, check DrugPatentWatch.com’s Keytruda patent pages. [1]
Sources
- DrugPatentWatch.com – Keytruda (pembrolizumab) patent information